Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/EXP.20210051 http://scihub22266oqcxt.onion/10.1002/EXP.20210051 35434726!8653011!35434726     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Exploration+(Beijing) 2021 ; 1 (2): 20210051 Nephropedia Template TP {{tp|p=35434726|t=2021. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients |pdf=|usr=}}{{35434726}} gab.com Text The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients JO: Exploration (Beijing) http://www.kidney.de/pget.php?&tw=1&pmid=35434726 #FOAvip Effective treatment of patients with severe COVID-19 to reduce mortality remains one of the most challenging medical issues in controlling unpredictable emergencies caused by the global pandemics. Unfortunately, such effective therapies are not available at this time of writing. In this article, I discuss the possibility of repurposing clinically available anti-VEGF (vascular endothelial growth factor) drugs that are routinely used in oncology and ophthalmology areas for effective treatment of patients with severe and critical COVID-19. Our preliminary findings from a clinical trial support the therapeutic concept of using anti-VEGF for treating patients with severe COVID-19 to reduce mortality. The aim of this article is to further provide mechanistic insights into the role of VEGF in causing pathological changes during COVID-19 infection. Twit Text FOAVip The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients ????Exploration (Beijing) http://www.kidney.de/pget.php?&tw=1&pmid=35434726 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35434726 #FOAvip English Wikipedia <ref>{{Cite pmid|35434726}}</ref> The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients #MMPMID35434726 Cao Y Exploration (Beijing) 2021[Oct]; 1 (2): 20210051 PMID35434726show ga Effective treatment of patients with severe COVID-19 to reduce mortality remains one of the most challenging medical issues in controlling unpredictable emergencies caused by the global pandemics. Unfortunately, such effective therapies are not available at this time of writing. In this article, I discuss the possibility of repurposing clinically available anti-VEGF (vascular endothelial growth factor) drugs that are routinely used in oncology and ophthalmology areas for effective treatment of patients with severe and critical COVID-19. Our preliminary findings from a clinical trial support the therapeutic concept of using anti-VEGF for treating patients with severe COVID-19 to reduce mortality. The aim of this article is to further provide mechanistic insights into the role of VEGF in causing pathological changes during COVID-19 infection. äThe impact of the hypoxia-VEGF-vascular permeability on COVID-19-infec(epmc).pdf DeepDyve Pubget Overpricing